Kymera Therapeutics, Inc. research snapshot
KYMR AI stock analysis as of the August 3, 2026 data cutoff reads Kymera Therapeutics, Inc. as a clinical-stage biopharmaceutical company developing oral targeted protein degraders for immunology. The stock closed at $103.40 on July 31, 2026, down from a June 25 intraday high of $130.05 that followed the announcement that enrollment in the Phase 2b BROADEN2 trial of KT-621 in atopic dermatitis was complete, implying a market capitalization near $8.51 billion using 82.26 million shares outstanding. Kymera held about $1.55 billion in cash, cash equivalents, and investments at March 31, 2026 per the Q1 2026 Form 10-Q, with Q1 2026 collaboration revenue of $34.37 million, R&D-driven operating loss of $84.15 million, and a net loss of $69.23 million, and the company expects its runway to last into 2029. The June 25, 2026 BROADEN2 update accelerated the expected topline data readout to year-end 2026, with KT-621 Phase 3 trials in atopic dermatitis planned by mid-2027, the BREADTH asthma Phase 2b data expected in late 2027, KT-579 Phase 1 data still expected in 2026, and the KT-485 IRAK4 Phase 1 trial dosed with Sanofi triggering a $20 million milestone. Q2 2026 financial results are scheduled for August 5, 2026, after this data cutoff. This Kymera Therapeutics AI stock analysis uses scenarios, technical levels, and source-backed facts for information only. It is not investment advice.
Current price
$103.40
Market cap
$8.51 billion calculated from 82.26 million shares
AI score
56 / 100
Rating
Clinical-stage targeted protein degradation platform with strong cash runway and high clinical risk
Trend status
Long-term uptrend, pullback from June highs with neutral momentum near support
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Kymera discovers and develops oral small molecule degraders, with wholly owned STAT6 and IRF5 programs plus partnered programs with Gilead and Sanofi. It has collaboration revenue but no approved product revenue. | High |
| Moat | The moat is based on target selection, degrader chemistry, discovery know-how, human-genetics-informed biology, patent families, and early clinical experience. It is a developing platform moat, not yet a commercial franchise. | Medium |
| Management | Founder, President, and CEO Nello Mainolfi has advanced the platform into Phase 2b and multiple partnerships. The July 27, 2026 appointment of Terence Rooney, former J&J immunology leader, as Chief Medical Officer refreshes clinical leadership ahead of the year-end 2026 KT-621 readout. | Medium |
| Financial trend | FY2025 collaboration revenue fell to $39.21 million from $47.07 million while net loss widened to $311.35 million. Q1 2026 revenue rose to $34.37 million, but the net loss was still $69.23 million and operating loss widened to $84.15 million as R&D spending continued. | High |
| Valuation | At $103.40, KYMR trades without meaningful PE or FCF support because TTM EPS was -$3.55 and TTM free cash flow was negative at about -$244 million. The market value mainly reflects pipeline probability, platform optionality, cash, and future partnering or approval assumptions. | High |
| Technical trend | Price was above the 50-day average of $98.06 and the 200-day average of $82.17, but RSI fell to 44.54 and the stock pulled back from the June 25 high of $130.05 to the $102 to $113 July range. The setup is long-term constructive but short-term neutral after the spike cooled. | Medium-high |
| Risk level | Risk is high because Kymera has no approved product, depends on clinical success, spends heavily on R&D, relies partly on collaboration milestones, and may experience large price moves around data and regulatory events. Short interest was about 9.90 million shares, roughly 12.04% of shares outstanding. | High |
| AI confidence | Confidence is high for descriptive facts and calculations, but lower for price outcomes because clinical data can overwhelm technical and balance-sheet signals. | High data confidence |
| Investment certainty | The company has financial endurance and credible platform evidence, but actual investment certainty is low until KT-621 and the broader degrader pipeline clear important clinical hurdles. | Low-medium |
KYMR AI stock forecast
The KYMR AI stock forecast is a conditional scenario framework, not a price promise. The three-scenario EPS command returned negative target prices because TTM EPS was -$3.55, so that output is not a useful intrinsic-value estimate. The ranges below are probability-sensitive market bands anchored to the $103.40 close, the $1.55 billion cash and investments runway, KT-621 milestones, analyst targets near $127.18, and the possibility of clinical or valuation repricing.
$145 to $195
More likely if KT-621 produces strong BROADEN2 Phase 2b atopic dermatitis data by year-end 2026 and advances toward Phase 3, KT-579 delivers clean early clinical data in 2026, KT-485 and the Sanofi and Gilead partnerships generate further milestones, and the market continues to value the platform as a multi-indication opportunity.
$90 to $135
More likely if KT-621 data are mixed but usable, development continues through 2027, the cash runway remains intact, and collaboration revenue offsets only a portion of the large R&D base while the market applies a wide clinical-stage biotech range around the current analyst consensus near $127.
$35 to $75
More likely if KT-621 misses efficacy or safety expectations, later-stage programs fail to validate the platform, partners reduce commitments, cash burn accelerates, or investors assign a much lower probability to approval and require future equity financing.
KYMR AI technical analysis
KYMR AI technical analysis is long-term constructive but short-term neutral as of the August 3, 2026 data cutoff. The stock closed at $103.40 on July 31, 2026, above the 50-day moving average of $98.06 and the 200-day moving average of $82.17, but below the June 25 intraday high of $130.05 and the early July highs near $120. StockAnalysis reported a 14-day RSI of 44.54, an average 20-day volume of about 593,353 shares, and a five-year beta of 1.96. These technical readings are a snapshot at the August 3 cutoff and can change with the next session.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $103.40 | StockAnalysis.com close for July 31, 2026, the latest completed trading session before the August 3 cutoff. |
| Near support | $102 to $105 | The July 31 low was $102.13, the July 28 low was $105.45, and the July 29 low was $104.12. A close below this zone would weaken the immediate consolidation structure. |
| Secondary support | $98 then $94 to $95 | The 50-day moving average is $98.06 and the June 23 low was $94.62. This is the next pullback area to monitor if the $102 to $105 zone fails. |
| Near resistance | $110 to $113 | The July 21 high was $113.83, the July 20 high was $119.83 but closed back lower, and the July 27 high was $113.00. A sustained close above this zone would mark a fresh breakout attempt. |
| Next resistance | $116 to $120 | The July 10 high was $120.60, the July 13 high was $117.28, and the July 17 high was $117.00. Above this sits the June 25 intraday high of $130.05. |
| Moving averages | SMA(50) $98.06; SMA(200) $82.17 | StockAnalysis snapshot updated for the July 31, 2026 close showed price above both rising long-term reference averages. The 50-day average sits about 5% below price. |
| Momentum | RSI(14) 44.54 | The RSI has cooled from an overbought area above 70 to a neutral 44.54 after the June and July pullback. It does not identify whether upcoming clinical news will be positive or negative. |
| Volume | About 593,000 shares average over 20 days | StockAnalysis reported average 20-day volume of 593,353 shares. Compare breakout or breakdown volume with trial, licensing, and earnings headlines. |
| Volatility | High; beta 1.96 | StockAnalysis reported a five-year beta of 1.96 and a 52-week range of $36.65 to $130.05. Clinical-stage biotech prices can gap beyond ordinary support and resistance levels. |
| Primary invalidation | Close below $98, then $94.62 | A decisive close below the 50-day average near $98 would weaken the recent structure. A break toward the June 23 low near $94.62 would require a broader thesis review. |
KYMR AI trading strategy
The KYMR AI trading strategy is a rules-based framework for a high-volatility clinical biotech. It is not personal advice and should be paired with live quotes, filings, position sizing, and a calendar of clinical, regulatory, and partnership events including the August 5, 2026 Q2 report and the year-end 2026 BROADEN2 readout.
Watch for KYMR to hold the $102 to $105 area, reclaim or break the $110 to $113 resistance band with confirming volume, and remain above the rising 50-day average near $98 while no negative clinical update changes the thesis.
A close below $98 should invalidate the short-term structure. A move toward $94.62 should trigger a full review of the clinical thesis rather than an automatic dip-buying assumption.
If KYMR pulls back toward $98 to $105 without new safety or efficacy concerns, compare the price move with KT-621 BROADEN2 timing, cash runway, partnership milestones, and the next disclosed data event.
Do not treat an oversold reading or a support touch as evidence that a clinical drawdown is temporary. Event-driven gaps can move through several technical levels.
Track KT-621 BROADEN2 atopic dermatitis data by year-end 2026, BREADTH asthma progress, KT-579 Phase 1 data in 2026, KT-485 development with Sanofi, KT-200 milestones with Gilead, the August 5, 2026 Q2 report, R&D spending, cash and investments, share issuance, and runway guidance.
Reduce confidence if the valuation depends on approval probability without new controlled data, if collaboration revenue becomes less reliable, or if cash burn shortens the stated runway.
Investment research summary
Kymera is trying to turn targeted protein degradation into oral medicines that remove disease-causing proteins rather than merely block them. Customers would pay only after clinical and regulatory proof shows that this mechanism improves outcomes, safety, convenience, or persistence versus existing immunology treatments.
The potential moat combines target selection, degrader chemistry, disease biology, proprietary discovery capabilities, patents, and a growing clinical dataset. It is not yet a proven commercial moat because no Kymera product has reached approval and competitors can pursue the same modality or disease targets.
The thesis fails if KT-621 does not reproduce Phase 1 signals in controlled Phase 2b trials, oral degradation creates safety or dosing problems, later programs lack therapeutic windows, partnerships do not produce durable economics, or cash burn and dilution overwhelm pipeline value.
Founder and CEO Nello Mainolfi has built a platform around immunology and advanced KT-621 into parallel Phase 2b programs. The June 2026 chairman transition to Felix Baker, with co-founder Bruce Booth remaining an independent director, and the July 2026 Chief Medical Officer transition from retiring Jared Gollob to Terence Rooney, show a maturing board and refreshed clinical leadership. The next management test is disciplined prioritization as clinical milestones multiply.
Targeted protein degradation is part of a broader shift toward medicines that address previously difficult intracellular targets. Kymera cites more than 140 million potential patients across Type 2 inflammatory diseases for STAT6, but the opportunity is only a market potential estimate until efficacy, safety, reimbursement, and differentiation are established.
At about $8.51 billion of equity value, KYMR has no earnings or free-cash-flow margin of safety because TTM EPS and FCF were negative. The balance sheet provides time, not intrinsic value. The current price therefore implies substantial confidence in KT-621, platform validation, partnerships, and eventual approval economics.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| KYMR latest completed-session price | $103.40 at the July 31, 2026 close, with an after-hours print of $104.00 | StockAnalysis.com quote page | August 3, 2026 |
| Market capitalization | $8.51 billion, computed as $103.40 x 82.26 million shares, matching the StockAnalysis.com quote and statistics pages | StockAnalysis.com quote and share statistics, verified with financial_rigor.py | August 3, 2026 |
| Shares outstanding reference | 82.26 million current share snapshot, up 14.80% year over year; the 2025 Form 10-K reported 81.642 million shares outstanding as of February 20, 2026 | StockAnalysis.com statistics and Kymera 2025 Form 10-K | August 3, 2026 |
| FY2025 collaboration revenue | $39.21 million, versus $47.07 million in 2024 and $78.59 million in 2023 | Kymera 2025 Form 10-K, StockAnalysis.com financials, and Macrotrends | August 3, 2026 |
| FY2025 loss and EPS | Net loss of $311.35 million and diluted EPS of -$3.69 | Kymera 2025 Form 10-K and StockAnalysis.com financials | August 3, 2026 |
| Q1 2026 financial results | $34.37 million collaboration revenue, $84.15 million operating loss, and $69.23 million net loss with EPS of -$0.71 | Kymera Q1 2026 Form 10-Q and StockAnalysis.com quarterly financials | August 3, 2026 |
| Cash and investments | $1.55 billion in cash, cash equivalents, and investments at March 31, 2026, with $1,540 million of shareholders equity; the company expects runway into 2029 | Kymera Q1 2026 Form 10-Q, SEC EDGAR XBRL, and StockAnalysis.com balance sheet | August 3, 2026 |
| Q2 2026 earnings date | August 5, 2026, announced July 28, 2026, after this data cutoff | Kymera press release July 28, 2026 | August 3, 2026 |
| Lead pipeline milestones | BROADEN2 Phase 2b enrollment complete with topline at year-end 2026 and Phase 3 in AD planned by mid-2027; BREADTH asthma Phase 2b data expected late 2027; KT-579 Phase 1 data expected in 2026; KT-485 Phase 1 dosed with a $20 million Sanofi milestone | Kymera June and July 2026 press releases | August 3, 2026 |
| Management transition | Terence Rooney, former immunology leader at Johnson and Johnson, appointed Chief Medical Officer on July 27, 2026, succeeding Jared Gollob, who retires and stays as advisor through year-end | Kymera press release July 27, 2026 | August 3, 2026 |
| Valuation snapshot | PE -29.13x, PB 5.52x, P/FCF -34.81x, FCF yield -2.87%, PS about 165x, and ROE near -19% based on the audited calculation inputs | financial_rigor.py valuation verification and StockAnalysis.com statistics | August 3, 2026 |
| Analyst consensus | Strong Buy from 24 analysts with an average target of $127.18, a median of $126.50, a low of $97, and a high of $155 | StockAnalysis.com forecast page | August 3, 2026 |
| Recent analyst actions, July 2026 | Deutsche Bank initiated Hold at $120 on July 30; Guggenheim raised to $135 on July 28; Piper Sandler maintained $140 and Mizuho raised to $140 on July 16; RBC downgraded to Hold at $115 on July 13; earlier moves included B. Riley at $155, Truist at $136, Canaccord at $129, and BofA at $125 | StockAnalysis.com forecast and news feed | August 3, 2026 |
| Short interest | 9.90 million shares short, about 12.04% of shares outstanding, 15.19% of float, and 7.75 days to cover | StockAnalysis.com statistics short selling section | August 3, 2026 |
| TTM financials | TTM revenue of $51.48 million, net loss of about $315 million, EPS of -$3.55, operating income of -$359.13 million, and free cash flow of about -$244 million | StockAnalysis.com financials and cash flow statement | August 3, 2026 |
| Technical snapshot | SMA50 $98.06, SMA200 $82.17, RSI 44.54, average 20-day volume 593,353 shares, beta 1.96, and 52-week range $36.65 to $130.05 | StockAnalysis.com statistics and history pages | August 3, 2026 |
This KYMR AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong if clinical results, financial results, regulation, partnerships, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
